Toll Free: 1-888-928-9744

Vernalis plc - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Vernalis plc - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Vernalis plc - Product Pipeline Review - 2014', provides an overview of the Vernalis plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vernalis plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Vernalis plc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Vernalis plc's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Vernalis plc's pipeline products

Reasons to buy

- Evaluate Vernalis plc's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Vernalis plc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Vernalis plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Vernalis plc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vernalis plc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Vernalis plc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Vernalis plc Snapshot 5
Vernalis plc Overview 5
Key Information 5
Key Facts 5
Vernalis plc - Research and Development Overview 6
Key Therapeutic Areas 6
Vernalis plc - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Vernalis plc - Pipeline Products Glance 14
Vernalis plc - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Vernalis plc - Early Stage Pipeline Products 15
Discovery Products/Combination Treatment Modalities 15
Vernalis plc - Drug Profiles 16
V-158866 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
V-81444 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Small Molecule to Inhibit Chk1 for Oncology 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Vernalis plc - Pipeline Analysis 19
Vernalis plc - Pipeline Products by Target 19
Vernalis plc - Pipeline Products by Route of Administration 20
Vernalis plc - Pipeline Products by Molecule Type 21
Vernalis plc - Pipeline Products by Mechanism of Action 22
Vernalis plc - Recent Pipeline Updates 23
Vernalis plc - Dormant Projects 25
Vernalis plc - Discontinued Pipeline Products 26
Discontinued Pipeline Product Profiles 26
alphadolone 26
BB-2827 26
indantadol 26
marimastat 26
solimastat 27
V-1003 27
V-10153 27
V-24343 27
VML-670 27
Vernalis plc - Company Statement 28
Vernalis plc - Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31
List of Tables
Vernalis plc, Key Information 5
Vernalis plc, Key Facts 5
Vernalis plc - Pipeline by Indication, 2014 7
Vernalis plc - Pipeline by Stage of Development, 2014 8
Vernalis plc - Monotherapy Products in Pipeline, 2014 9
Vernalis plc - Partnered Products in Pipeline, 2014 10
Vernalis plc - Partnered Products/ Combination Treatment Modalities, 2014 11
Vernalis plc - Out-Licensed Products in Pipeline, 2014 12
Vernalis plc - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
Vernalis plc - Phase II, 2014 14
Vernalis plc - Discovery, 2014 15
Vernalis plc - Pipeline by Target, 2014 19
Vernalis plc - Pipeline by Route of Administration, 2014 20
Vernalis plc - Pipeline by Molecule Type, 2014 21
Vernalis plc - Pipeline Products by Mechanism of Action, 2014 22
Vernalis plc - Recent Pipeline Updates, 2014 23
Vernalis plc - Dormant Developmental Projects,2014 25
Vernalis plc - Discontinued Pipeline Products, 2014 26
Vernalis plc, Subsidiaries 29 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify